News from pronai therapeutics inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jan 09, 2017, 07:00 ET ProNAi Relaunched as Sierra Oncology to Advance DDR-Based Cancer Drugs

- Sierra Oncology to trade on NASDAQ under the symbol 'SRRA' - - Company to present at the BIOTECH Showcase in San Francisco on January 11th -...

Nov 14, 2016, 07:00 ET ProNAi to Present at the Jefferies 2016 London Healthcare Conference

- "Beyond PARP - Next Generation DDR Therapeutics" scheduled for 8:00 am on November 17th, 2016 - VANCOUVER, Nov 14, 2016 /PRNewswire/ - ProNAi...

Nov 10, 2016, 07:00 ET ProNAi Therapeutics Reports Third Quarter 2016 Results

VANCOUVER, Nov. 10, 2016 /PRNewswire/ - ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a clinical stage drug development company focused on advancing...

Oct 13, 2016, 07:00 ET ProNAi Therapeutics to Present at the 15th Annual BIO Investor Forum in San Francisco

- "Beyond PARP - Next Generation DDR Therapeutics" scheduled for 9:00 am on October 19th, 2016 - VANCOUVER, Oct. 13, 2016 /PRNewswire/ - ProNAi...

Sep 27, 2016, 07:00 ET ProNAi Licenses Oncology Drug Targeting DNA Damage Response Checkpoint Kinase 1 (Chk1) from CRT Pioneer Fund, UK

- PNT737 currently in Phase 1 clinical trials at the Royal Marsden, London, UK - - Potential to exploit cancer-driving genetic mutations to achieve...

Aug 12, 2016, 07:00 ET ProNAi Therapeutics Reports Second Quarter 2016 Results

VANCOUVER, Aug. 12, 2016 /PRNewswire/ - ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a drug development company focused on advancing targeted...

Jun 06, 2016, 07:00 ET ProNAi Reports Interim Data from Wolverine Phase 2 Trial of PNT2258 in DLBCL

- Company provides update on PNT2258 and DNAi platform - VANCOUVER, June 6, 2016 /PRNewswire/ - ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a drug...

Jun 01, 2016, 07:00 ET ProNAi Therapeutics Appoints Dr. Christian Hassig as Senior Vice President of Research

VANCOUVER, June 1, 2016 /PRNewswire/ - ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a clinical-stage oncology company advancing novel targeted...

May 26, 2016, 07:00 ET ProNAi Licenses Cancer Drug Candidate Targeting CDC7 from Carna Biosciences

- Small molecule kinase inhibitor AS-141 positioned for clinical trials in 2017 - - CDC7 is an important regulator of DNA replication and DNA damage...

May 18, 2016, 06:00 ET ProNAi to Report Wolverine Phase 2 Interim Results on June 6th at ASCO

- ProNAi to hold Analyst & Investor Event at 7:00am CT on June 6th - - ProNAi to Present at Jefferies 2016 Healthcare Conference in New York on June...

May 10, 2016, 07:00 ET ProNAi Therapeutics Reports First Quarter 2016 Results

VANCOUVER, May 10, 2016 /PRNewswire/ - ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a clinical-stage oncology company advancing novel therapeutics for...

Mar 18, 2016, 07:00 ET ProNAi Therapeutics Appoints Jeffrey H. Cooper and Tran Nguyen to its Board of Directors

- Company opens San Francisco area office - VANCOUVER, March 18, 2016 /PRNewswire/ - ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a clinical-stage...

Mar 14, 2016, 07:00 ET ProNAi Therapeutics Granted Orphan Drug Designation for PNT2258 for the Treatment of Diffuse Large B-Cell Lymphoma

VANCOUVER, March 14, 2016 /PRNewswire/ - ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a clinical-stage oncology company advancing novel therapeutics for ...

Mar 03, 2016, 07:00 ET ProNAi Reports 2015 Year-End Financial and Operational Results

VANCOUVER, March 3, 2016 /PRNewswire/- ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a clinical-stage oncology company advancing novel therapeutics for...

Dec 22, 2015, 07:00 ET ProNAi to Present at JP Morgan 34th Annual Healthcare Conference in San Francisco

VANCOUVER, Dec. 22, 2015 /PRNewswire/ - ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a clinical-stage oncology company pioneering a novel class of...

Dec 18, 2015, 07:00 ET ProNAi Therapeutics Added to NASDAQ Biotechnology Index

VANCOUVER, Dec 18, 2015 /PRNewswire/ - ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a clinical-stage oncology company pioneering a novel class of...

Dec 03, 2015, 07:00 ET ProNAi Therapeutics Appoints Dr. Keith Anderson and Dr. Gregg Smith to its Senior Management Team

VANCOUVER, Dec 3, 2015 /PRNewswire/ - ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a clinical-stage oncology company pioneering a novel class of...

Nov 11, 2015, 07:00 ET ProNAi to Present at Jefferies Autumn 2015 Global Healthcare Conference in London

VANCOUVER, Nov. 11, 2015 /PRNewswire/ - ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a clinical-stage oncology company pioneering a novel class of...

Nov 05, 2015, 07:00 ET ProNAi Therapeutics Reports Third Quarter 2015 Results

VANCOUVER, Nov. 5, 2015 /PRNewswire/ - ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a clinical-stage oncology company pioneering a novel class of...

Oct 29, 2015, 07:00 ET ProNAi Initiates 'Brighton' Phase II Trial of PNT2258 in Patients with Richter's Transformation

- First patient dosed in clinical trial evaluating DNAi interference (DNAi®) - VANCOUVER, Oct. 29, 2015 /PRNewswire/ - ProNAi Therapeutics, Inc....

Aug 21, 2015, 07:00 ET ProNAi Therapeutics Reports Second Quarter 2015 Results

Completed Upsized Initial Public Offering, Raising Gross Proceeds of $158.4 Million Advanced Clinical Programs for PNT2258 in DLBCL and Richter's...

Jul 21, 2015, 05:18 ET ProNAi Therapeutics Announces Closing of IPO and Full Exercise of the Underwriters' Option to Purchase Additional Shares

VANCOUVER, July 21, 2015 /PRNewswire/ - ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a clinical-stage oncology company pioneering a novel class of...

Jul 15, 2015, 07:46 ET ProNAi Therapeutics Announces Pricing of Initial Public Offering

VANCOUVER, July 15, 2015 /PRNewswire/ - ProNAi Therapeutics, Inc., a clinical-stage oncology company pioneering a novel class of therapeutics based...

Jun 23, 2015, 08:00 ET ProNAi Appoints Dr. Barbara Klencke as Chief Development Officer

VANCOUVER, June 23, 2015 /PRNewswire/ - ProNAi Therapeutics Inc., a clinical-stage oncology company pioneering a novel class of therapeutics based on ...

Jun 18, 2015, 08:00 ET ProNAi Appoints Dr. Nicole Onetto and Mr. Robert Pelzer to its Board of Directors

VANCOUVER, June 18, 2015 /PRNewswire/ - ProNAi Therapeutics, a clinical-stage oncology company pioneering a novel class of therapeutics based on its...